Abstract
Background Amyotrophic lateral sclerosis (ALS) is an old onset devastating neurodegenerative disorder. Young-onset ALS cases especially sporadic ones who are between 25 and 45 years are rarely affected by the disease. Despite the identification of numerous candidate genes associated with ALS, the aetiology of the disease remains elusive due to extreme genetic and phenotypic variability. The advent of affordable whole exome sequencing has opened new avenues for unraveling the disease’s pathophysiology better.
Methods and Results Our aim was to determine the genetic basis of an Indian-origin, young onset sporadic ALS patient with very rapid deterioration of the disease course without any cognitive decline who was screened for mutations in major ALS candidate genes by Whole exome sequencing. Variants detected were reconfirmed by Sanger Sequencing. The clinicopathological features were investigated and two heterozygous missense variants harboring each in ANXA11, in one of the four conserved C terminal domains (R452W) and another in the SIGMAR1 (R208W) were thus identified respectively. Both of these variants were predicted to be damaging by pathogenicity prediction tools and various In silico methods.
Conclusions Our study revealed two potentially pathogenic variants in two ALS candidate genes. The genetic makeup of ALS patients from India has been the subject of a few prior studies, but none of them examined ANXA11 and SIGMAR1 genes so far. These results establish the framework for additional research into the pathogenic processes behind these variations that result in sporadic ALS disease and further our understanding of the genetic makeup of Indian ALS patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The first author acknowledges Department of Science and Technology (DST), India for providing Junior Research Fellowship (JRF) & Senior Research Fellowship (SRF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Institute of Science, Banaras Hindu University (Ref No: I.Sc/ECM-XIV/2022-23/)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data generated or analysed during this study are included in this published article.
